Dilated cardiomyopathy induced by bicalutamide
10.3760/cma.j.cn114015-20211025-01093
- VernacularTitle:比卡鲁胺致扩张型心肌病
- Author:
Lu YANG
1
;
Huanyu LIN
;
Shanshan XIE
;
Jinjin WAN
;
Jian'gen AO
;
Weifang ZHANG
Author Information
1. 南昌大学第二附属医院心血管内科，南昌 330006
- Publication Type:Journal Article
- Keywords:
Androgen antagonists;
Cardiomyopathy, dilated;
Bicaluramide
- From:
Adverse Drug Reactions Journal
2022;24(5):278-280
- CountryChina
- Language:Chinese
-
Abstract:
A 63-year-old male patient with prostate cancer was treated with bicalutamide (50 mg orally, once daily) combined with goserelin sustained-release implant (10.8 mg subcutaneously once every 3 months), and 27 months later, goserelin was replaced by leuprorelin sustained-release microspheres (3.75 mg subcutaneously once a month). At the 32nd month after bicalutamide treatment, the patient developed progressive dyspnea and decreased physical activity without obvious inducement. At the 36th month after administration of bicalutamide, the patient developed mild edema of both lower limbs. Cardiac color Doppler ultrasound showed that the diameters of left and right atrium were 48 and 45 mm respectively, the left ventricular diameters at end systole and end diastole and the right ventricle diameter were 49, 57, and 28 mm respectively, and the left ventricular ejection fraction was 28%. Laboratory test showed that the precursor of B-type brain natriuretic peptide was 4 533 ng/L. Dilated cardiomyopathy caused by bicalutamide was considered. Bicalutamide was discontinued, leuprorelin was injected subcutaneously at a dose as before, and metoprolol, sacubitril and valsartan, and spironolactone were given. After one month of treatment, the patient′s above symptoms disappeared. Cardiac color Doppler ultrasound showed that the diameters of left and right atrium were 40 and 44 mm, respectively, the left ventricular diameters at end systole and end diastole and the right ventricle diameter were 44, 53, and 29 mm, respectively, and the left ventricular ejection fraction was 36%. The precursor of type B brain natriuretic peptide was 1 539 ng/L
